Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
- Companies
- Company details
Sinclair Pharmaceuticals
Sinclair Pharma plc, a rapidly growing UK based pharmaceutical company is seeking distributors around the world.
The company in detail
Profile
Sinclair Pharma plc is an international pharmaceutical company focused on the sourcing and acquisition of niche, patented, late-stage or fully developed innovative products with the potential to reach the marketplace within a short timeframe.
Sinclair Pharma products are focused in the field of oral health, oncology support and dermatology. There are currently nine main products, seven of which are registered with regulatory authorities in either the EU and/or the US. The Company has already appointed distributors in over 40 countries for the Group's products.
The Group's strategy principally relies on the sourcing and acquisition of late stage or fully developed innovative products which have the potential to reach the marketplace within a relatively short time frame. This strategy is designed to reduce development risks and associated costs. The Directors intend to grow the Group by exploiting the Group's current products and IPR, and by making acquisitions. It is the Company's intention to register most of the Group's products that are not already registered in both the EU and the US as not all of the Group's products have been registered with the appropriate regulatory authorities in both the EU and the US. The Company will also pursue opportunities to introduce the Group's products in Japan.
To date, Sinclair Pharma has acquired two companies in Sweden and one in Italy for their portfolio of pharmaceutical products and IPR in the oral health, oncology support or dermatology fields.
Since the acquisition of the initial three companies, Sinclair Pharma has secured registration and licensing agreements for a number of these three companies' products. It intends to do the same with select products from the Euroderm portfolio.
For all licensing enquiries, please contact either Javier Boza or Sharon Collins.
For product information only, please contact Manisha Abay.
Partnering strategy/interests
The Group's strategy principally relies on the sourcing and acquisition of late stage or fully developed innovative products which have the potential to reach the marketplace within a relatively short time frame.
The Company's intends to register most of the Group's products that are not already registered in both the EU and the US and to pursue opportunities to introduce the Group's products in Japan.
Out-licensing
New cream formulation to manage the symptoms of atopic dermatitis. More
Decapinol Gel, offers a novel and convenient way of treating periodontal disease. It contains 3 key ingredients - Delmopinol Hydrochloride (5mg/ml), Polyvinylpyrrolidone (PVP) and Hyaluronic Acid. More
Decapinol Gum Applicator offers a novel and convenient way of treating periodontal disease. The unique delivery system was developed specifically for dental professionals; its unique ergonomic design makes it easy to apply. More
Decapinol Spray is the most recent line extension of Decapinol mouth rinse, Decapinol toothpaste and Decapinol Gel, and provides both the clinician and patient with an alternative in treating gingivitis and periodontitis. More
Decapinol toothpaste containing Sodium Fluoride (NaF) 0.11% and Delmopinol 0.2% is a new addition to the Decapinol family and is indicated for the treatment of gingivitis and periodontitis. More
Decapinol™ rinse contains a cationic surfactant Delmopinol Hydrochloride 2mg/ml; Decapinol rinse has a unique mode of action, which prevents the attachment as well as the adherence of plaque bacteria to the teeth, gingiva and to itself. More
SALINUM™ is a saliva substitute, indicated for the relief of symptoms of dry mouth, or xerostomia. More
New non steroidal topical cream for treatment of seborrheic dermatitis More
Sinlice is a new anti-lice composition specifically formulated as a dry-on, suffocation-based product. It has been designed to adhere to hair shafts and keratins. More
SPHR900 is a topical composition based on extracts of plants suitably selected to ensure anti-herpes type 1 activity. More
SPHR913 anti-wrinkle serum is an innovative product researched and developed to lessen the effects of skin ageing. The key ingredient is telmesteine (N-carbetoxy-4-tiazolidin carboxylic acid). More
SST is a pleasant-tasting pastille made up of organic acids and a calcium salt buffer for the management of Xerostomia (dry mouth). It is designed to support the production of saliva without causing or accelerating tooth decay. More
T-go (SPHO220) is indicated for the management of teething, including the relief of its most common symptoms, such as painful and swollen gums. More
This ophthalmic solution provides relief of the symptoms associated with dry eye, improving the quality of life among sufferers in both mild-moderate and chronic dry eye cases. More
Xclair is a cream, indicated for the management of radiation-induced dermatitis, including relief and management of the most common signs and symptoms such as pruritus, erythema, burning and pain. More
R&D
To view this information, you must subscribe to Partneringtools.
Partnerships
To view this information, you must subscribe to Partneringtools.
Deals
To view this information, you must subscribe to Partneringtools.
Press Releases
(29th Jan 2008) 29th January 2008, Godalming, UK: Sinclair Pharma plc ("Sinclair"), the international specialty pharmaceutical company, announces the EU registration of its pipeline product SPHR900 for herpes simplex. More
(12th Dec 2007) 12 December 2007, Godalming, UK: Sinclair Pharma plc ("Sinclair"), the international specialty pharmaceutical company, announces EU registration of its pipeline product for head lice, SPHR980. More
(6th Dec 2007) 6 December 2007, Godalming, UK: Sinclair Pharma plc ("Sinclair": SPH:L), the international specialty pharmaceutical company, announces EU registration of its pipeline product for symptom relief for teething infants, SPHO220. More
(16th Oct 2007) 16 October, Godalming, UK: Sinclair Pharma plc ( More
(4th Oct 2007) 4 October 2007, Godalming, UK: Sinclair Pharma plc ("Sinclair", SPH:L), the international specialty pharmaceutical company, today presents data at the World Congress of Dermatology, to support its novel pipeline product for acne, SPHD420. More
(27th Sep 2007) 27 September 2007, Godalming, UK: Sinclair Pharma plc ("Sinclair", SPH:L), the specialty pharmaceutical company, announces that it has licensed the exclusive US rights of its seborrheic dermatitis product, Sebclair to Dr Reddy's Laboratories, Inc. More
(25th Sep 2007) 25 September, 2007, Godalming, UK. Sinclair Pharma plc, announces the UK launches of Atopiclair Cream for Atopic Dermatitis (eczema) and Xclair Cream for radiation dermatitis (skin damage during radiotherapy), by its UK company Ashbourne Pharma More
(12th Sep 2007) 12 September 2007, Godalming, UK. Sinclair Pharma plc (SPH.L), the specialty pharmaceutical company, announces it has made its first regulatory filing in Japan. More
(5th Jun 2007) 5 June 2007, Godalming, UK. Sinclair Pharma plc ("Sinclair", LSE:SPH), the international specialty pharmaceutical company today announces that Intendis GmbH ("Intendis"), has launched Sinclair's AtopiclairTM cream in five European countries. More
(24th May 2007) 24 May, 2007, Godalming, UK. Sinclair Pharma plc, the specialty pharmaceutical company, announces that its French subsidiary CS Dermatologie ("CSD") has acquired the Fazol brand in France, Morocco, Algeria and Tunisia, from Janssen Pharmaceutica NV. More
(30th Apr 2007) 30 April, Godalming, UK. Sinclair Pharma plc (SPH.L), the specialty pharmaceutical company, today announced that cumulative net US sales since launch of AtopiclairTM, by its distributor Graceway Pharmaceuticals, LLC ( More
(21st Feb 2007) 21 February 2007, Godalming, UK: Sinclair Pharma plc ("Sinclair", SPH:L), the international specialty pharmaceutical company, announces that it has signed a deal with Dexcel Pharma to sell its flagship mouth ulcer product, Aloclair®, in the UK. More
(29th Jan 2007) 29 January 2007, Godalming, UK: Sinclair Pharma plc ( More
(16th Jan 2007) 16 January 2007, Godalming, UK. Sinclair Pharma plc (SPH.L), the specialty pharmaceutical company, announces that its UK subsidiary Ashbourne Pharmaceuticals has signed a marketing agreement with the German company Hennig Arzneimittel GmbH. More
(29th Jun 2006) Sinclair Pharma plc, the specialty pharmaceutical ompany, announces that it has licensed the exclusive US rights of one of its key products, Decapinol® Rinse, to OraPharma, Inc., a subsidiary of Johnson & Johnson More
(16th Mar 2006) Frost & Sullivan the international management consultancy, has awarded its prestigious 2006 Oral and Dental Care Product of the Year Award to Sinclair Pharma plc for Decapinol® More
(28th Nov 2005) AGM STATEMENT More
(22nd Aug 2005) Sinclair Pharma plc announces today that John O. Butler Mexico, part of the international Sunstar Group, has signed a marketing and distribution agreement for Mexico for all three Aloclair® products, Sinclair's treatments for mouth ulcers. More
(26th Jul 2005) Sinclair Pharma plc today announces the signing of three new sales and marketing agreements. More
(12th Jul 2005) Sinclair Pharma plc announces that it has obtained EU registration for two new oral health products - Decapinol® Toothpaste and DecapiDecapinol® Gel More
(7th Jul 2005) Sinclair Pharma plc announces two new sales and marketing agreements for Xclair™, its product for the treatment of radiation dermatitis. More
(29th Jun 2005) Three new licensing agreements in North America and three in Columbia More
(29th Jun 2005) Sinclair Pharma plc, the specialty pharmaceutical company, announces that it is today holding an R&D briefing in London for investors and analysts. More
(21st Jun 2005) More
(31st May 2005) Sinclair Pharma plc announces that Decapinol®, the company's oral rinse for the treatment and prevention of gingivitis has been launched in Italy, the product's first market More
(25th Apr 2005) Sinclair Pharma plc are pleased to announce the appointment of Derek Williams as Chief Operating Officer of Sinclair Pharmaceuticals Ltd, More
(25th Apr 2005) Sinclair Pharma plc today announces three new licensing agreements, two for Atopiclair™ and the extension of an existing agreement for Aloclair® Rinse to include Aloclair® Spray. More
(19th Apr 2005) Sinclair Pharma plc announces today that Decapinol®, its oral rinse for the treatment of gingivitis (gum inflammation), has received registration approval from the FDA as a prescription medical device. More
(31st Mar 2005) Significant regulatory and commercial progress with 3 product approvals and 7 licensing deals More
(24th Jan 2005) Sincalir Pharma plc announces today that Aloclair® Spray has received approval from the FDA as a medical device. More
(4th Jan 2005) Sinclair Pharma plc is pleased to announce its first distribution agreement for Decapinol, a novel treatment for gingivitis with an intelligent mode of action. More
(22nd Dec 2004) Sinclair Pharma plc has acquired Euroderm, a dermatology company with a specialist sales force in Italy. More
(21st Dec 2004) Sinclair Pharma plc is pleased to announce the licensing of the US rights to Atopiclair cream for atopic dermatitis to Chester Valley Pharmaceuticals. More
Senior management
To view this information, you must subscribe to Partneringtools.
Board of directors
To view this information, you must subscribe to Partneringtools.
Head office
Sinclair Pharmaceuticals
Unit 4
Godalming Business Centre
Woolsack Way
Godalming
Surrey
GU7 1XW
United Kingdom
Tel: (44) (0)1483 410 600
Fax: (44) (0)1483 410620
www | email
Unit 4
Godalming Business Centre
Woolsack Way
Godalming
Surrey
GU7 1XW
United Kingdom
Tel: (44) (0)1483 410 600
Fax: (44) (0)1483 410620
www | email
Contact details
Sharon Collins
Business Development Manager
Business Development Manager
Company figures
Related categories
- Industry sector
- Drug delivery / Topical
- Drug delivery / Topical / Dermatological
- Drug delivery / Topical / Oral
- Medical device / Therapeutic device
- Pharmaceutical / OTC/Non-Prescription
- Pharmaceutical / Personal Care
- Pharmaceutical / Prescription
- Therapeutic target
- Dermatological
- Dermatological / Wound healing
- Dermatological / Eczema
- Oncology
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us